Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

被引：6

作者：

Jacques, Sarah K. ^{[1
,2
]}

McKeown, Janet ^{[3
]}

Grover, Piyush ^{[3
]}

Johson, Douglas B. ^{[4
]}

Zaremba, Anne ^{[5
]}

Dimitriou, Florentia ^{[6
,7
]}

Weiser, Roi ^{[24
]}

Farid, Mohamad ^{[8
]}

Namikawa, Kenjiro ^{[9
]}

Sullivan, Ryan J. ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Lebbe, Celeste ^{[12
]}

Hamid, Omid ^{[13
]}

Zager, Jonathan S. ^{[14
]}

Michielin, Olivier ^{[15
]}

Neyns, Bart ^{[16
]}

Nakamura, Yasuhiro ^{[17
]}

Robert, Caroline ^{[18
,19
]}

Mehnert, Janice ^{[25
]}

Ascierto, Paolo A. ^{[26
]}

Bhave, Prachi ^{[23
]}

Park, Benjamin ^{[4
]}

Zimmer, Lisa ^{[5
]}

Mangana, Joanna ^{[6
,11
]}

Mooradian, Megan ^{[10
]}

Placzke, Joanna ^{[7
]}

Allayous, Clare ^{[12
]}

Oliva, Isabella C. Glitza ^{[24
]}

Mehmi, Inderjit ^{[13
]}

Depalo, Danielle ^{[14
]}

Wicky, Alexandre ^{[15
]}

Schwarze, Julia K. ^{[16
]}

Roy, Severine ^{[18
]}

Boatwright, Christina ^{[25
]}

Vanella, Vito ^{[26
]}

Long, Georgina, V ^{[3
,20
,21
]}

Menzies, Alexander M. ^{[3
,20
,21
,22
]}

Lo, Serigne N. ^{[3
,20
]}

Carlino, Matteo S. ^{[1
,2
,3
,27
]}

机构：

[1] Westmead Hosp, Dept Med Oncol, Sydney, Australia

[2] Blacktown Hosp, Dept Med Oncol, Sydney, Australia

[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia

[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[5] Univ Hosp Essen, Dept Dermatol Venereol & Allergol, Essen, Germany

[6] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

[7] Univ Zurich, Fac Med, Zurich, Switzerland

[8] Natl Canc Ctr, Singapore, Singapore

[9] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[10] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[12] Univ Paris Cite, St Louis Hosp, Canc Inst AP HP Nord Paris Cite, INSERM U976,AP HP Dermatooncol, Paris, France

[13] Angeles Clin, Los Angeles, CA USA

[14] Moffit Canc Ctr, Dept Cutaneous Oncol, Tampa, FL USA

[15] Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland

[16] Univ Ziekenhuis Brussel, Brussels, Belgium

[17] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Skin Oncol Dermatol, Saitama, Japan

[18] Inst Gustave Roussy, Villejuif, France

[19] Paris Saclay Univ, Villejuif, France

[20] Univ Sydney, Fac Med & Hlth, Sydney, Australia

[21] Royal North Shore Hosp, Sydney, Australia

[22] Mater Hosp, Sydney, Australia

[23] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia

[24] MD Anderson Canc Ctr, Houston, TX USA

[25] NYU Langone, New York, NY USA

[26] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy

[27] Westmead Hosp, Crown Princess Mary Canc Ctr, 166-174 Hawkesbury Rd, Westmead, NSW 2145, Australia

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 199卷

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Acral melanoma; Mucosal melanoma; Adjuvant; Immunotherapy; Anti-PD1; IMMUNE CHECKPOINT INHIBITORS;

D O I：

10.1016/j.ejca.2024.113563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. Objective: To determine the efficacy of adjuvant PD1 in resected AM or MM. Design: An international, retrospective cohort study Setting: Data up to November 2021 collected from 20 centres across 10 countries. Participants: One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. Main outcomes and measures: Recurrence -free survival (RFS), distant metastasis -free survival (DMFS) and overall survival (OS) were investigated. Results: Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR -0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p -value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p -value 0.3799], DMFS or OS. Conclusion and relevance: After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.

引用

页数：8

共 50 条

[41] Real-Life Cohort of Patients With Resected High-Risk Melanoma Treated by Adjuvant Anti-PD1 Therapy
Benzoni, Liza
Eberhardt, Anais
Milley, Sarah
Idoudi, Safa
Trefcon, Camille
Romain-Scelle, Nicolas
Thomas, Luc
Dalle, Stephane
CANCER MEDICINE, 2025, 14 (06):
[42] Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy
Forschner, Andrea
Niessner, Heike
Sinnberg, Tobias
Eigentler, Thomas
Amaral, Teresa
Seith, Ferdinand
Garbe, Claus
Biskup, Saskia
Battke, Florian
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (06): : 867 - 871
[43] Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.
Colle, Elise
Dalle, Stephane
Mortier, Laurent
Guillot, Bernard
Dutriaux, Caroline
Leccia, Marie Therese
Dalac, Sophie
Legoupil, Delphine
De Quatrebarbes, Julie
Montaudie, Henri
Arnault, Jean-Philippe
Brunet-Possenti, Florence
Saiag, Philippe
Momenzadeh, Mathieu
Dreno, Brigitte
Porcher, Raphael
Oriano, Bastien
Lebbe, Celeste
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Lian, B.
Si, L.
Chi, Z. H.
Sheng, X. N.
Kong, Y.
Wang, X.
Tian, H.
Li, K.
Mao, L. L.
Bai, X.
Tang, B. X.
Yan, X. Q.
Li, S. M.
Zhou, L.
Dai, J.
Tang, X. W.
Ran, F. W.
Yao, S.
Guo, J.
Cui, C. L.
ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
[45] Outcomes for stage 3 and resected stage 4 melanoma patients treated with adjuvant immunotherapy at Alfred health
Nadkarni, Lalitagauri
Haydon, Andrew
Cherk, Martin
Nadebaum, David
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 44 - 44
[46] Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Owen, C. N.
Shoushtari, A. N.
Chauhan, D.
Palmieri, D. J.
Lee, B.
Rohaan, M. W.
Mangana, J.
Atkinson, V
Zaman, F.
Young, A.
Hoeller, C.
Hersey, P.
Dummer, R.
Khattak, M. A.
Millward, M.
Patel, S. P.
Haydon, A.
Johnson, D. B.
Lo, S.
Blank, C. U.
Sandhu, S.
Carlino, M. S.
Larkin, J. M. G.
Menzies, A. M.
Long, G., V
ANNALS OF ONCOLOGY, 2020, 31 (08) : 1075 - 1082
[47] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
Patrinely, James R., Jr.
Baker, Laura X.
Davis, Elizabeth J.
Song, Haocan
Ye, Fei
Johnson, Douglas B.
CANCER, 2020, 126 (15) : 3448 - 3455
[48] Neutrophil subset investigation in stage III melanoma patients undergoing anti-PD-1 immunotherapy or anti-BRAF/MEK target therapy
Trocchia, Marialuisa
Cristinziano, Leonardo
Modestino, Luca
Ventrici, Annagioia
Loffredo, Stefania
Ferrara, Anne Lise
Tocchetti, Carlo Gabriele
Troiani, Teresa
Marone, Gianni
Galdiero, Maria Rosaria
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1105 - 1105
[49] Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
Christensen, Stine K.
Winther, Mette L.
Laursen, Ida J.
Madsen, Freja S.
Brink, Carsten
Brix, Thomas H.
Ellebaek, Eva
Svane, Inge Marie
Hansen, Frederikke S.
Haslund, Charlotte
Laursen, Olivia K.
Schmidt, Henrik
Larsen, Ida D.
Bastholt, Lars
Ruhlmann, Christina H.
SUPPORTIVE CARE IN CANCER, 2024, 32 (05)
[50] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Parakh, Sagun
Park, John J.
Mendis, Shehara
Rai, Rajat
Xu, Wen
Lo, Serigne
Drummond, Martin
Rowe, Catherine
Wong, Annie
McArthur, Grant
Haydon, Andrew
Andrews, Miles C.
Cebon, Jonathan
Guminski, Alex
Kefford, Richard F.
Long, Georgina V.
Menzies, Alexander M.
Klein, Oliver
Carlino, Matteo S.
BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1558 - 1563

← 1 2 3 4 5 →